MRK  Merck & Company Inc.

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

175.5B

Vuru Grade

47.84/100

Current Price

$61.57
-0.99 (-1.58%)

Growth Price

$47.53
Overvalued by 22.80%

Stability Price

$23.65
Overvalued by 61.58%

Company Metrics

  • 34.06 P/E
  • 4.14 P/S
  • 3.96 P/B
  • 1.837 EPS
  • 10.80% Cash ROIC
  • 0.98 Cash Ratio
  • 1.77 / 2.83% Dividend
  • 10.86M Avg. Vol.
  • 2.85B Shares
  • 175.5B Market Cap.

Company Description

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company's Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, ...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Cheaper Vaccines By Serum Institute Of India To Seize Merck & Co.'s (MRK ...
Bidness ETC - 22 hours ago
The move is expected to cut into the market shares of pharmaceutical giants like Merck & Co., Inc. (NYSE:MRK), GlaxoSmithKline plc (ADR) (NYSE:GSK), Sanofi SA (ADR) (NYSE:SNY), and Pfizer Inc. (NYSE:PFE).
Merck & Co. A Holding Of Latest 13F Filers
Forbes - 13 hours ago
At Holdings Channel, we have reviewed the latest batch of the 23 most recent 13F filings for the 12/31/2014 reporting period, and noticed that Merck & Co., Inc (NYSE: MRK) was held by 14 of these funds. When hedge fund managers appear to be thinking ...
Merck & Co., Inc. (MRK) Takes Hepatitis C Drug Victrelis Off The US Market
Bidness ETC - Jan 22, 2015
Merck & Co., Inc. (NYSE:MRK) notified the US Food and Drug Administration (FDA) earlier this week that it has decided to no longer sell its hepatitis C drug Victrelis in the US.
Merck & Co. Inc. (MRK) Closes 0.41% Down on the Day for January 27
Equities.com - Jan 27, 2015
Merck & Co. Inc. currently has a total float of 2.85 billion shares and moves 11.22 million a day, on average. The stock opened at $62.88 on January 27 and traded between a low of $62.13 and a high of $63.02.
Trade of the Day: Merck (MRK)
Investorplace.com - Jan 23, 2015
Today's recommendation is for a call trade on Merck & Co., Inc. (MRK), a pharmaceutical company whose key products include Januvia (for diabetes), Zetia (for cholesterol) and Gardasil (vaccine for HPV).
Merck & Co. Inc. (MRK) Closes 1.77% Down on the Day for January 28
Equities.com - 12 hours ago
Merck & Co. Inc. currently has a total float of 2.85 billion shares and moves 11.11 million a day, on average. The stock opened at $62.82 on January 28 and traded between a low of $61.32 and a high of $62.96.
Merck & Co., Inc. Analyst Rating Update
Stafford Daily - 48 minutes ago
Merck & Co., Inc. (NYSE:MRK) has received a Neutral rating, according to the latest rank of 3 from research firm, Zacks.
Merck & Co., Inc. Short Interest Disclosure - Bar and Graph Report
Large Outflow of Money Witnessed in Merck & Co., Inc. Shares - Rock Hill Daily
Exclusive: Merck funds tests of lower Zilmax doses as seen seeking way to ...
Reuters - Jan 19, 2015
CHICAGO (Reuters) - Merck & Co Inc is funding the testing of lower dosages of its controversial cattle growth drug Zilmax, in a move that livestock experts say is crucial if the company is to resume sales of the product to the U.S.
First Call Rating Update on Merck & Co., Inc.
Stafford Daily - Jan 26, 2015
Merck & Co., Inc. (NYSE:MRK) has been rated as Buy in the consensus recommendation of First Call Corporation, a division of Thomson Reuters.
Merck & Co. Inc. (MRK) Closes 0.16% Down on the Day for January 23
Equities.com - Jan 23, 2015
Merck & Co. Inc. currently has a total float of 2.85 billion shares and moves 11.86 million a day, on average. The stock opened at $62.46 on January 23 and traded between a low of $62.41 and a high of $63.00.